KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model.

Pratik Bhagunde, Natasha Penner, Brian A Willis, Robert Bell, Arnaud Charil, Michael C Irizarry, Steven Hersch, Larisa Reyderman

CPT Pharmacometrics Syst Pharmacol 15(2) e70173

PMID41543367
PMCIDPMC12823306
DOI10.1002/psp4.70173
发表日期2026-01-16
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图;FIGURE 5:非 KM 图。
摘要

摘要

Lecanemab is a humanized IgG1 monoclonal antibody binding with high affinity to protofibrils of amyloid-beta (Aβ) protein. In clinical studies, lecanemab has been shown to reduce amyloid markers in early symptomatic Alzheimer's disease and slow decline on clinical endpoints of cognition and function. Nonlinear mixed-effects modeling assessed the correlation between amyloid PET and change in CDR-SB using data from lecanemab phase 2 study (Study 201) and phase 3 study (Study 301; Clarity AD). Data from placebo-treated subjects were used to establish a disease-progression model; the effect of amyloid reduction on disease progression was defined using data from lecanemab-treated subjects. CDR-SB scores were used with beta regression to fit a Richard's function parameterized in terms of baseline CDR-SB, intrinsic rate of disease progression, shape, and precision of the beta distribution. Simulations were conducted to evaluate the impact of lecanemab treatment over 4 years. Baseline CDR-SB was predicted by diagnosis and baseline mini-mental state examination (BMMSE) score. Intrinsic rate of disease progression was predicted by amyloid PET and BMMSE. Amyloid PET was a better predictor of drug effect than lecanemab exposure, demonstrating amyloid reduction as a surrogate marker of efficacy. Simulations projected the difference in CDR-SB between lecanemab and placebo treated subjects continued increasing over 4 years. Patients with low baseline amyloid and less severe disease were projected to have slower disease progression and better outcomes with lecanemab treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Schematic of PK‐amyloid‐positron emission tomography (PET) and PK‐amyloid‐PET‐CDR‐SB PK/PD models.
非 KM Figure
FIGURE 2Intrinsic rate of disease progression (IR) as a Function of baseline amyloid positron emission tomography (PET) using piecewise function of baseline amyloid PET.
非 KM Figure
FIGURE 3Model‐predicted and mean (95% CI) observed CDR‐SB profiles for 10 mg/kg biweekly Lecanemab and Placebo over 48 months. LEC10‐BW, lecanemab 10 mg/kg biweekly. Figure lines are model‐predicted CDR‐SB profiles for 10 mg/kg biweekly Lecanemab and Placebo over 48 months, with colored bands representing 95% confidence intervals around model predictions; dots with bars are observed mean CDR‐SB with 95% confidence intervals.
非 KM Figure
FIGURE 4Simulated amyloid PET and change from baseline in CDR‐SB for representative subjects treated with 10 mg/kg Lecanemab biweekly (LEC10‐BW) or placebo.
非 KM Figure
FIGURE 5Simulated mean amyloid PET and CDR‐SB profiles for 10 mg/kg biweekly for 48 months comparing initiation of monthly 10 mg/kg IV maintenance dose at 18 months.
非 KM Figure